As coronavirus variants and subvariants account for a majority of reported cases in the U.S., vaccine-makers are racing to test and prove efficacy against specific variants. Here are three updates on variant-specific candidates from Sanofi-GSK and Moderna:
Read the full post on Becker's Hospital Review - Healthcare News
